What does this research mean for the field?

Intrapericardial treatment of autoreactive pericarditis with 300 mg/m2/24h of triamcinolone is as effective as a 600 mg/m2/24h regimen in preventing symptom recurrence and effusion relapse, but results in significantly fewer side effects such as iatrogenic Cushing syndrome. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 1, 2002European Heart JournalOpen Access

Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone. The way to avoid side effects of systemic corticosteroid therapy

View Full Paper

Ask AI

Bookmark

Why the study?

Does intrapericardial triamcinolone 300 mg/m2/24h compared to 600 mg/m2/24h reduce side effects while maintaining efficacy in preventing effusion recurrence in patients with autoreactive pericarditis?

Population

84 patients with autoreactive pericarditis. Group 1: n=54, 50% males, mean age 48.9 +/- 14.3 years. Group 2…

Comparison

Intrapericardial instillation of triamcinolone… vs Intrapericardial instillation of triamcinolone…

Design

Cohort

Follow-up

1 year

Authors

BMBernhard MaischGeneral Cardiology

Discussion

Member takes

Implication

May favor 300 mg/m2/24h intrapericardial triamcinolone to limit Cushing syndrome; leaves open randomized confirmation of equivalent efficacy.

Structured PICO

Population

84 patients with autoreactive pericarditis (identified from 260 consecutive patients with pericarditis/myopericarditis). Group 1: n=54, 50% males, mean age 48.9 +/- 14.3 years. Group 2: n=30, 46.7% males, mean age 52.5 +/- 12.7 years.

Intervention

Intrapericardial instillation of triamcinolone 600 mg x m(-2) x 24 h(-1)

Comparator

Intrapericardial instillation of triamcinolone 300 mg x m(-2) x 24 h(-1)

Outcome

Symptomatic improvement and prevention of effusion recurrence at 3 months and 1 yearcomposite

Intrapericardial triamcinolone at 300 mg/m2/24h is as effective as 600 mg/m2/24h for preventing recurrence of autoreactive pericarditis but with significantly fewer side effects like iatrogenic Cushing syndrome.

Cite This Study

Bernhard Maisch (2002) studied this question.

synapsesocial.com/papers/6a1a29f90fc4dc4e42436b6c https://doi.org/10.1053/euhj.2002.3152

View Full Paper

Ask AI

Bookmark

Implication

May favor 300 mg/m2/24h intrapericardial triamcinolone to limit Cushing syndrome; leaves open randomized confirmation of equivalent efficacy.

Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone. The way to avoid side effects of systemic corticosteroid therapy

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone. The way to avoid side effects of systemic corticosteroid therapy

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider